Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells
There is currently no FDA-approved GLP-1 patch on the market , and for good reason
No, retatrutide remains investigational as of early 2026
Conclusion Starting GLP-1 therapy is an important step toward better health, and its natural to want guidance that makes the journey feel simple and supported
However, those with Medicare, Medicaid, and Tricare are not eligible for GLP-1s through LifeMD, due to coverage limitations for these medications
In the central nervous system, they act on appetite-regulating centers in the hypothalamus, reducing hunger and increasing satiety signals